<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00049842</url>
  </required_header>
  <id_info>
    <org_study_id>P02570</org_study_id>
    <nct_id>NCT00049842</nct_id>
  </id_info>
  <brief_title>Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)</brief_title>
  <official_title>PEG-Intron(TM) Maintenance Therapy vs. an Untreated Control Group for Prevention of Progression of Fibrosis in Adult Subjects With Chronic Hepatitis C With Hepatic Fibrosis (METAVIR Fibrosis Score of F2 or F3), Who Failed Therapy With PEG-Intron Plus REBETOL(R) (in Protocol No. P02370)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety and efficacy of PEG-Intron versus no
      treatment for the prevention of fibrosis progression in adult participants with moderate to
      severe liver fibrosis secondary to chronic hepatitis C, who failed PEG-Intron plus Rebetol
      treatment in protocol P02370 (NCT00039871).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibrosis Response Status (ie, Improvement, no Change, or the Worsening of the Fibrosis Score in Participants With Baseline METAVIR Fibrosis Score of F2 or F3).</measure>
    <time_frame>Baseline to up to Month-36</time_frame>
    <description>Definitions:
Fibrosis scoring: F0 (no fibrosis), F1 (stellate enlargement of portal tract without septa formation, F2 (enlargement of portal tract with rare septa formation, F3 (numerous septa without cirrhosis), F4 (cirrhosis).
Improved: Participants whose METAVIR fibrosis score at up to Month-36 decreases by 1 or more units compared to baseline.
No Change: Participants whose METAVIR fibrosis score at up to Month-36 is the same as the baseline score.
Worsened: Participants whose METAVIR fibrosis score at up to Month-36 increases by 1 or more units compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammation Response Status (ie, Improvement, no Change, or the Worsening of the METAVIR Activity Score as Compared to Baseline)</measure>
    <time_frame>Baseline to up to Month-36</time_frame>
    <description>Activity Scoring: A0 (no histological activity), A1 (minimal activity), A2 (moderate activity), A3 (severe activity), A4 (lobular chronic hepatitis).
Changes in liver inflammation defined as follows:
Improved: Participants whose METAVIR activity score at up to Month-36 decreases by 1 or more units compared to baseline.
No Change: Participants whose METAVIR activity score at up to Month-36 is the same as the baseline score.
Worsened: Participants whose METAVIR activity score at up to Month-36 increases by 1 or more units compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to up to Month-36 in the METAVIR Fibrosis Score (Using a Continuous Scale)</measure>
    <time_frame>Baseline to up to Month-36</time_frame>
    <description>The change of Metavir Fibrosis Score = Metavir Fibrosis Score at up to Month-36 - Metavir Fibrosis Score at Baseline.
Fibrosis scoring: 0 (no fibrosis), 1 (stellate enlargement of portal tract without septa formation, 2 (enlargement of portal tract with rare septa formation, 3 (numerous septa without cirrhosis), 4 (cirrhosis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Whose METAVIR Fibrosis Score Did Not Worsen (ie, the Response Status of Improved/no Change) During Treatment Compared to Baseline</measure>
    <time_frame>Baseline to up to Month-36</time_frame>
    <description>Definitions:
Fibrosis scoring: F0 (no fibrosis), F1 (stellate enlargement of portal tract without septa formation, F2 (enlargement of portal tract with rare septa formation, F3 (numerous septa without cirrhosis), F4 (cirrhosis).
Improved: Participants whose METAVIR fibrosis score at up to Month-36 decreases by 1 or more units compared to baseline.
No Change: Participants whose METAVIR fibrosis score at up to Month-36 is the same as the baseline score.
Worsened: Participants whose METAVIR fibrosis score at up to Month-36 increases by 1 or more units compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in the METAVIR Activity Score (Using a Continuous Scale)</measure>
    <time_frame>Baseline to up to Month-36</time_frame>
    <description>The change of Metavir Activity Score = Metavir Activity Score at up to Month-36 - Metavir Activity Score at Baseline.
Activity Scoring: 0 (no histological activity), 1 (minimal activity), 2 (moderate activity), 3 (severe activity), 4 (lobular chronic hepatitis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With no Worsening (ie, the Response Status of Improved/ no Change) in the METAVIR Activity Score During the Treatment.</measure>
    <time_frame>Baseline to up to Month-36</time_frame>
    <description>Definitions:
Activity Scoring: A0 (no histological activity), A1 (minimal activity), A2 (moderate activity), A3 (severe activity), A4 (lobular chronic hepatitis).
Improved: Participants whose METAVIR activity score at up to Month-36 decreases by 1 or more units compared to baseline.
No Change: Participants whose METAVIR activity score at up to Month-36 is the same as the baseline score.
Worsened: Participants whose METAVIR activity score at up to Month-36 increases by 1 or more units compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">540</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>PEG-Intron (peginterferon alfa-2b) 0.5 µg/kg Weekly (QW)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-Intron 0.5 µg/kg Weekly (QW) subcutaneously (SC) as maintenance therapy for 36 months with 4-week follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>peginterferon alfa-2b (SCH 54031)</intervention_name>
    <description>0.5 µg/kg Weekly QW SC for 36 months</description>
    <arm_group_label>PEG-Intron (peginterferon alfa-2b) 0.5 µg/kg Weekly (QW)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at entry in study P02370 (NCT00039871) 18-65 years;

          -  Nonresponder to PEG-Intron plus Rebetol in study P02370

        Exclusion Criteria:

          -  Participants who did not participate in the P02370 study.

          -  Any medical condition, including but not limited to decompensated liver disease,
             malignancy or substance abuse, that developed during the P02370 study which could
             interfere with the participant's participation in and completion of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2002</study_first_submitted>
  <study_first_submitted_qc>November 14, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2002</study_first_posted>
  <results_first_submitted>October 7, 2010</results_first_submitted>
  <results_first_submitted_qc>December 17, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2011</results_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW)</title>
          <description>PEG-Intron 0.5 µg/kg weekly (QW) subcutaneously (SC) as maintenance therapy for 36 months with 4-week follow-up</description>
        </group>
        <group group_id="P2">
          <title>Untreated Control</title>
          <description>Participants were observed (no treatment given) for 36 months with 4-week follow-up</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="270"/>
                <participants group_id="P2" count="270"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="192"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet protocol eligibility</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="218">Population is all treatment phase completers plus some who discontinued the treatment phase.</participants>
                <participants group_id="P2" count="194">Population is all treatment phase completers plus some who discontinued the treatment phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
                <participants group_id="P2" count="189"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW)</title>
          <description>PEG-Intron 0.5 µg/kg weekly (QW) subcutaneously (SC) as maintenance therapy for 36 months with 4-week follow-up</description>
        </group>
        <group group_id="B2">
          <title>Untreated Control</title>
          <description>Participants were observed (no treatment given) for 36 months with 4-week follow-up</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="270"/>
            <count group_id="B2" value="270"/>
            <count group_id="B3" value="540"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fibrosis Response Status (ie, Improvement, no Change, or the Worsening of the Fibrosis Score in Participants With Baseline METAVIR Fibrosis Score of F2 or F3).</title>
        <description>Definitions:
Fibrosis scoring: F0 (no fibrosis), F1 (stellate enlargement of portal tract without septa formation, F2 (enlargement of portal tract with rare septa formation, F3 (numerous septa without cirrhosis), F4 (cirrhosis).
Improved: Participants whose METAVIR fibrosis score at up to Month-36 decreases by 1 or more units compared to baseline.
No Change: Participants whose METAVIR fibrosis score at up to Month-36 is the same as the baseline score.
Worsened: Participants whose METAVIR fibrosis score at up to Month-36 increases by 1 or more units compared to baseline.</description>
        <time_frame>Baseline to up to Month-36</time_frame>
        <population>Population is Intent-to-Treat (ITT). Participants with missing Month-36 biopsy slides were classified as “no change”, including 88 participants in the PEG-Intron group and 104 participants in the Observed group.</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW)</title>
            <description>PEG-Intron 0.5 µg/kg weekly (QW) subcutaneously (SC) as maintenance therapy for 36 months with 4-week follow-up</description>
          </group>
          <group group_id="O2">
            <title>Untreated Control</title>
            <description>Participants were observed (no treatment given) for 36 months with 4-week follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Fibrosis Response Status (ie, Improvement, no Change, or the Worsening of the Fibrosis Score in Participants With Baseline METAVIR Fibrosis Score of F2 or F3).</title>
          <description>Definitions:
Fibrosis scoring: F0 (no fibrosis), F1 (stellate enlargement of portal tract without septa formation, F2 (enlargement of portal tract with rare septa formation, F3 (numerous septa without cirrhosis), F4 (cirrhosis).
Improved: Participants whose METAVIR fibrosis score at up to Month-36 decreases by 1 or more units compared to baseline.
No Change: Participants whose METAVIR fibrosis score at up to Month-36 is the same as the baseline score.
Worsened: Participants whose METAVIR fibrosis score at up to Month-36 increases by 1 or more units compared to baseline.</description>
          <population>Population is Intent-to-Treat (ITT). Participants with missing Month-36 biopsy slides were classified as “no change”, including 88 participants in the PEG-Intron group and 104 participants in the Observed group.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammation Response Status (ie, Improvement, no Change, or the Worsening of the METAVIR Activity Score as Compared to Baseline)</title>
        <description>Activity Scoring: A0 (no histological activity), A1 (minimal activity), A2 (moderate activity), A3 (severe activity), A4 (lobular chronic hepatitis).
Changes in liver inflammation defined as follows:
Improved: Participants whose METAVIR activity score at up to Month-36 decreases by 1 or more units compared to baseline.
No Change: Participants whose METAVIR activity score at up to Month-36 is the same as the baseline score.
Worsened: Participants whose METAVIR activity score at up to Month-36 increases by 1 or more units compared to baseline.</description>
        <time_frame>Baseline to up to Month-36</time_frame>
        <population>Population is ITT. Participants with missing Month-36 biopsy slides were classified as “no change”, including 88 participants in the PEG-Intron group and 104 participants in the Observed group.</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW)</title>
            <description>PEG-Intron 0.5 µg/kg weekly (QW) subcutaneously (SC) as maintenance therapy for 36 months with 4-week follow-up</description>
          </group>
          <group group_id="O2">
            <title>Untreated Control</title>
            <description>Participants were observed (no treatment given) for 36 months with 4-week follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammation Response Status (ie, Improvement, no Change, or the Worsening of the METAVIR Activity Score as Compared to Baseline)</title>
          <description>Activity Scoring: A0 (no histological activity), A1 (minimal activity), A2 (moderate activity), A3 (severe activity), A4 (lobular chronic hepatitis).
Changes in liver inflammation defined as follows:
Improved: Participants whose METAVIR activity score at up to Month-36 decreases by 1 or more units compared to baseline.
No Change: Participants whose METAVIR activity score at up to Month-36 is the same as the baseline score.
Worsened: Participants whose METAVIR activity score at up to Month-36 increases by 1 or more units compared to baseline.</description>
          <population>Population is ITT. Participants with missing Month-36 biopsy slides were classified as “no change”, including 88 participants in the PEG-Intron group and 104 participants in the Observed group.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                    <measurement group_id="O2" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to up to Month-36 in the METAVIR Fibrosis Score (Using a Continuous Scale)</title>
        <description>The change of Metavir Fibrosis Score = Metavir Fibrosis Score at up to Month-36 - Metavir Fibrosis Score at Baseline.
Fibrosis scoring: 0 (no fibrosis), 1 (stellate enlargement of portal tract without septa formation, 2 (enlargement of portal tract with rare septa formation, 3 (numerous septa without cirrhosis), 4 (cirrhosis).</description>
        <time_frame>Baseline to up to Month-36</time_frame>
        <population>ITT population who had both pre and up to Month-36 METAVIR fibrosis score.</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW)</title>
            <description>PEG-Intron 0.5 µg/kg weekly (QW) subcutaneously (SC) as maintenance therapy for 36 months with 4-week follow-up</description>
          </group>
          <group group_id="O2">
            <title>Untreated Control</title>
            <description>Participants were observed (no treatment given) for 36 months with 4-week follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to up to Month-36 in the METAVIR Fibrosis Score (Using a Continuous Scale)</title>
          <description>The change of Metavir Fibrosis Score = Metavir Fibrosis Score at up to Month-36 - Metavir Fibrosis Score at Baseline.
Fibrosis scoring: 0 (no fibrosis), 1 (stellate enlargement of portal tract without septa formation, 2 (enlargement of portal tract with rare septa formation, 3 (numerous septa without cirrhosis), 4 (cirrhosis).</description>
          <population>ITT population who had both pre and up to Month-36 METAVIR fibrosis score.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.977"/>
                    <measurement group_id="O2" value="0.31" spread="1.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants Whose METAVIR Fibrosis Score Did Not Worsen (ie, the Response Status of Improved/no Change) During Treatment Compared to Baseline</title>
        <description>Definitions:
Fibrosis scoring: F0 (no fibrosis), F1 (stellate enlargement of portal tract without septa formation, F2 (enlargement of portal tract with rare septa formation, F3 (numerous septa without cirrhosis), F4 (cirrhosis).
Improved: Participants whose METAVIR fibrosis score at up to Month-36 decreases by 1 or more units compared to baseline.
No Change: Participants whose METAVIR fibrosis score at up to Month-36 is the same as the baseline score.
Worsened: Participants whose METAVIR fibrosis score at up to Month-36 increases by 1 or more units compared to baseline.</description>
        <time_frame>Baseline to up to Month-36</time_frame>
        <population>Population is ITT. Participants with missing Month-36 biopsy slides were classified as “no change”, including 88 participants in the PEG-Intron group and 104 participants in the Observed group.</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW)</title>
            <description>PEG-Intron 0.5 µg/kg weekly (QW) subcutaneously (SC) as maintenance therapy for 36 months with 4-week follow-up</description>
          </group>
          <group group_id="O2">
            <title>Untreated Control</title>
            <description>Participants were observed (no treatment given) for 36 months with 4-week follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Whose METAVIR Fibrosis Score Did Not Worsen (ie, the Response Status of Improved/no Change) During Treatment Compared to Baseline</title>
          <description>Definitions:
Fibrosis scoring: F0 (no fibrosis), F1 (stellate enlargement of portal tract without septa formation, F2 (enlargement of portal tract with rare septa formation, F3 (numerous septa without cirrhosis), F4 (cirrhosis).
Improved: Participants whose METAVIR fibrosis score at up to Month-36 decreases by 1 or more units compared to baseline.
No Change: Participants whose METAVIR fibrosis score at up to Month-36 is the same as the baseline score.
Worsened: Participants whose METAVIR fibrosis score at up to Month-36 increases by 1 or more units compared to baseline.</description>
          <population>Population is ITT. Participants with missing Month-36 biopsy slides were classified as “no change”, including 88 participants in the PEG-Intron group and 104 participants in the Observed group.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved/No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in the METAVIR Activity Score (Using a Continuous Scale)</title>
        <description>The change of Metavir Activity Score = Metavir Activity Score at up to Month-36 - Metavir Activity Score at Baseline.
Activity Scoring: 0 (no histological activity), 1 (minimal activity), 2 (moderate activity), 3 (severe activity), 4 (lobular chronic hepatitis).</description>
        <time_frame>Baseline to up to Month-36</time_frame>
        <population>ITT population who had both pre and up to Month-36 METAVIR activity score.</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW)</title>
            <description>PEG-Intron 0.5 µg/kg weekly (QW) subcutaneously (SC) as maintenance therapy for 36 months with 4-week follow-up</description>
          </group>
          <group group_id="O2">
            <title>Untreated Control</title>
            <description>Participants were observed (no treatment given) for 36 months with 4-week follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in the METAVIR Activity Score (Using a Continuous Scale)</title>
          <description>The change of Metavir Activity Score = Metavir Activity Score at up to Month-36 - Metavir Activity Score at Baseline.
Activity Scoring: 0 (no histological activity), 1 (minimal activity), 2 (moderate activity), 3 (severe activity), 4 (lobular chronic hepatitis).</description>
          <population>ITT population who had both pre and up to Month-36 METAVIR activity score.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="182"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.709"/>
                    <measurement group_id="O2" value="0.11" spread="0.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With no Worsening (ie, the Response Status of Improved/ no Change) in the METAVIR Activity Score During the Treatment.</title>
        <description>Definitions:
Activity Scoring: A0 (no histological activity), A1 (minimal activity), A2 (moderate activity), A3 (severe activity), A4 (lobular chronic hepatitis).
Improved: Participants whose METAVIR activity score at up to Month-36 decreases by 1 or more units compared to baseline.
No Change: Participants whose METAVIR activity score at up to Month-36 is the same as the baseline score.
Worsened: Participants whose METAVIR activity score at up to Month-36 increases by 1 or more units compared to baseline.</description>
        <time_frame>Baseline to up to Month-36</time_frame>
        <population>Population is ITT. Participants with missing Month-36 biopsy slides were classified as “no change”, including 88 participants in the PEG-Intron group and 104 participants in the Observed group.</population>
        <group_list>
          <group group_id="O1">
            <title>PEG-Intron (Peginterferon Alfa-2b) 0.5 µg/kg Weekly (QW)</title>
            <description>PEG-Intron 0.5 µg/kg weekly (QW) subcutaneously (SC) as maintenance therapy for 36 months with 4-week follow-up</description>
          </group>
          <group group_id="O2">
            <title>Untreated Control</title>
            <description>Participants were observed (no treatment given) for 36 months with 4-week follow-up</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With no Worsening (ie, the Response Status of Improved/ no Change) in the METAVIR Activity Score During the Treatment.</title>
          <description>Definitions:
Activity Scoring: A0 (no histological activity), A1 (minimal activity), A2 (moderate activity), A3 (severe activity), A4 (lobular chronic hepatitis).
Improved: Participants whose METAVIR activity score at up to Month-36 decreases by 1 or more units compared to baseline.
No Change: Participants whose METAVIR activity score at up to Month-36 is the same as the baseline score.
Worsened: Participants whose METAVIR activity score at up to Month-36 increases by 1 or more units compared to baseline.</description>
          <population>Population is ITT. Participants with missing Month-36 biopsy slides were classified as “no change”, including 88 participants in the PEG-Intron group and 104 participants in the Observed group.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved/No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249"/>
                    <measurement group_id="O2" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PEG-Intron</title>
        </group>
        <group group_id="E2">
          <title>Untreated Control</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>SPLENOMEGALY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>CARDIAC AMYLOIDOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>CORONARY OSTIAL STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>DEAFNESS UNILATERAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>MENIERE'S DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL FIBROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND CALCULUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>VARICES OESOPHAGEAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>DISEASE PROGRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>HEPATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>LIVER DISORDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>CRYOGLOBULINAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>FUNGAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS SALMONELLA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>BRAIN CONTUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>HEPATIC HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>MENISCUS LESION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>NARCOTIC INTOXICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>SKIN INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>SKIN LACERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>SKULL FRACTURED BASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>ULNA FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>TYPE 1 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>PATELLOFEMORAL PAIN SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>PLICA SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>BENIGN NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>BREAST CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>BURKITT'S LYMPHOMA STAGE IV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>METASTATIC RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>MULTIPLE MYELOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>COGNITIVE DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>COMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>HEMIPLEGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>HYDROCEPHALUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL ABUSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>DEPRESSED MOOD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>GLOMERULONEPHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>NEPHROTIC SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>URETERIC OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>LUNG INFILTRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>COLD SWEAT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>PRURIGO</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>SUBSTANCE ABUSER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIAL THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>ILIAC ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>VASCULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="234" subjects_at_risk="270"/>
                <counts group_id="E2" subjects_affected="200" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="98" subjects_affected="32" subjects_at_risk="270"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="39" subjects_affected="18" subjects_at_risk="270"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="270"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="270"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="270"/>
                <counts group_id="E2" events="30" subjects_affected="22" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="40" subjects_affected="28" subjects_at_risk="270"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="270"/>
                <counts group_id="E2" events="26" subjects_affected="22" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="270"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="92" subjects_affected="46" subjects_at_risk="270"/>
                <counts group_id="E2" events="38" subjects_affected="30" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="270"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="82" subjects_affected="66" subjects_at_risk="270"/>
                <counts group_id="E2" events="68" subjects_affected="59" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="59" subjects_affected="34" subjects_at_risk="270"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="219" subjects_affected="18" subjects_at_risk="270"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>INJECTION SITE REACTION</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="270"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="43" subjects_affected="32" subjects_at_risk="270"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="94" subjects_affected="30" subjects_at_risk="270"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATOMEGALY</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="270"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="26" subjects_affected="19" subjects_at_risk="270"/>
                <counts group_id="E2" events="24" subjects_affected="14" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="26" subjects_affected="21" subjects_at_risk="270"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="79" subjects_affected="50" subjects_at_risk="270"/>
                <counts group_id="E2" events="47" subjects_affected="40" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="46" subjects_affected="32" subjects_at_risk="270"/>
                <counts group_id="E2" events="41" subjects_affected="24" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="228" subjects_affected="46" subjects_at_risk="270"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DISTURBANCE IN ATTENTION</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="270"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="270"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="429" subjects_affected="76" subjects_at_risk="270"/>
                <counts group_id="E2" events="31" subjects_affected="24" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="34" subjects_affected="25" subjects_at_risk="270"/>
                <counts group_id="E2" events="35" subjects_affected="25" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="41" subjects_affected="33" subjects_at_risk="270"/>
                <counts group_id="E2" events="34" subjects_affected="24" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="88" subjects_affected="56" subjects_at_risk="270"/>
                <counts group_id="E2" events="58" subjects_affected="46" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="270"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="43" subjects_affected="38" subjects_at_risk="270"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="270"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="42" subjects_affected="36" subjects_at_risk="270"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="270"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="270"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="270"/>
                <counts group_id="E2" events="32" subjects_affected="27" subjects_at_risk="270"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No public presentation/publication of any interim results will be made by any principal investigator (PI) or any other member of the study staff without the Sponsor's prior written consent. The PI further agrees to provide to the sponsor 30 days prior to submission, review copies that report any results of the study. The sponsor shall have the right to review, comment, and edit. If the parties disagree, the PI agrees to meet with the sponsor to discuss and resolve any such issues/disagreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

